Transient appearance of EDTA dependent pseudothrombocytopenia in a patient with 2019 novel coronavirus pneumonia

Han, Li; Wang, Bangqin; Ning, Leping; Luo, Yu; Xiang, Shulin

doi:10.1080/09537104.2020.1760231

Cited by 25 publications

(24 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are also reports of pseudothrombocytopenia [ 56 ]. In this report, treatment with COVID-19 eliminated the phenomenon of pseudothrombocytopenia, as well as the disappearance of SARS-Cov-2 antibody.…”

Section: Decreased Platelet and Lymphocyte Countsmentioning

confidence: 99%

COVID-19-associated coagulopathy and disseminated intravascular coagulation

2020

View full text Add to dashboard Cite

The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms. The most frequently reported coagulation/fibrinolytic abnormality in COVID-19 is the increase in d -dimer, and its relationship with prognosis has been discussed. However, limits exist to the utility of evaluation by d -dimer alone. In addition, since the coagulation/fibrinolytic condition sometimes fluctuates within a short period of time, regular examinations in recognition of the significance of the examination are desirable. The pathophysiology of disseminated intravascular coagulation (DIC) associated with COVID-19 is very different from that of septic DIC, and both thrombotic and hemorrhagic pathologies should be noted. COVID-19 thrombosis includes macro- and microthrombosis, with diagnosis of the latter depending on markers of coagulation and fibrinolysis. Treatment of COVID-19 is classified into antiviral treatment, cytokine storm treatment, and thrombosis treatment. Rather than providing uniform treatment, the treatment method most suitable for the severity and stage should be selected. Combination therapy with heparin and nafamostat is expected to develop in the future. Fibrinolytic therapy and adsorption therapy require further study

show abstract

Section: Decreased Platelet and Lymphocyte Countsmentioning

confidence: 99%

COVID-19-associated coagulopathy and disseminated intravascular coagulation

2020

View full text Add to dashboard Cite

show abstract

“…4,[8][9][10] Li and colleagues reported transient EDTA-dependent pseudothrombocytopenia in a patient with COVID-19 infection; however, platelet clumping resolved with use of a citrate tube, and the EDTA-dependent pseudothrombocytopenia phenomenon resolved with patient recovery. 11 The frequency of COVID-19-related pseudothrombocytopenia is currently unknown.…”

Section: Discussionmentioning

confidence: 99%

Pan-Pseudothrombocytopenia in COVID-19: A Harbinger for Lethal Arterial Thrombosis?

2020

Federal Practitioner

View full text Add to dashboard Cite

show abstract

“…This phenomenon can be persistent or transient, sometimes showing alternating periods without aggregates generation [ 10 ]. A recent case of transient PTCP has been described in a COVID-19 patient during viral immunization [ 2 ].…”

Section: Mechanisms Prevalence and Risk Factorsmentioning

confidence: 99%

“…Reported for the first time in 1969 [ 1 ], pseudothrombocytopenia (PTCP) has been increasingly described in patients suffering from various disorders and more recently even in patients with coronavirus disease 2019 (COVID-19) [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Pseudothrombocytopenia—A Review on Causes, Occurrence and Clinical Implications

Lardinois

Favresse

Châtelain

et al. 2021

JCM

View full text Add to dashboard Cite

Pseudothrombocytopenia (PTCP), a relative common finding in clinical laboratories, can lead to diagnostic errors, overtreatment, and further (even invasive) unnecessary testing. Clinical consequences with potential life-threatening events (e.g., unnecessary platelet transfusion, inappropriate treatment including splenectomy or corticosteroids) are still observed when PTCP is not readily detected. The phenomenon is even more complex when occurring with different anticoagulants. In this review we present a case of multi-anticoagulant PTCP, where we studied different parameters including temperature, amikacin supplementation, measurement methods, and type of anticoagulant. Prevalence, clinical risk factors, pre-analytical and analytical factors, along with clinical implications, will be discussed. The detection of an anticoagulant-dependent PTCP does not necessarily imply the presence of specific disorders. Conversely, the incidence of PTCP seems higher in patients receiving low molecular weight heparin, during hospitalization, or in men aged 50 years or older. New analytical technologies, such as fluorescence or optical platelet counting, will be soon overturning traditional algorithms and represent valuable diagnostic aids. A practical laboratory approach, based on current knowledge of PTCP, is finally proposed for overcoming spuriously low platelet counts.

show abstract

Transient appearance of EDTA dependent pseudothrombocytopenia in a patient with 2019 novel coronavirus pneumonia

Cited by 25 publications

References 12 publications

COVID-19-associated coagulopathy and disseminated intravascular coagulation

COVID-19-associated coagulopathy and disseminated intravascular coagulation

Pan-Pseudothrombocytopenia in COVID-19: A Harbinger for Lethal Arterial Thrombosis?

Pseudothrombocytopenia—A Review on Causes, Occurrence and Clinical Implications

Contact Info

Product

Resources

About